Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Lung Cancer
Rearrangement During Transfection (RET) Fusions and Their Role as Oncogenic Drivers
Read More
Lung Cancer
Molecular Profiling Is Critical for Optimizing NSCLC Therapy
Read More
Lung Cancer
Response to Immune Checkpoint Inhibitors Among Patients with NSCLC with RET Rearrangements
Read More
Lung Cancer
Clinical Trials of Targeted Therapies in RET-Rearranged NSCLC
Read More
Lung Cancer
Unmet Needs in NSCLC
Read More
HOPA Highlights
,
Biomarkers
,
Immunotherapy
,
Lung Cancer
The Intersection of Immunotherapy and Targeted Therapy in Lung Cancer
Meg Barbor, MPH
Meg Barbor, MPH
Read More
FDA Oncology Update
,
Lung Cancer
Zepzelca New Therapy Approved for Metastatic Small-Cell Lung Cancer
Read More
FDA Oncology Update
,
Lung Cancer
FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation
Read More
FDA Oncology Update
,
Lung Cancer
Opdivo plus Yervoy and Chemotherapy Approved as First-Line Therapy for Metastatic NSCLC, Regardless of PD-L1 Expression
Read More
FDA Oncology Update
,
Lung Cancer
Tecentriq Approved as First-Line Therapy for Metastatic NSCLC with High PD-L1 Expression
Read More
7
8
9
10
11
12
Page 10 of 12
Results 91 - 100 of 114